The dividend ETF world has its usual suspects. If you ask investors to name a dividend ETF, chances are you will hear the same handful of tickers. VIG, VYM, DGRO, and SCHD have earned their place as household names. But familiar does not always mean best.
The Schwab US Dividend Equity ETF (SCHD), the one your uncle, who calls himself a “value investor,” has been talking about for three years, is closing in on the Vanguard Dividend Appreciation ETF (VIG) for the top spot in the category.
SCHD held $113.2 billion in net assets as of Sept. 3, while VIG sits at $130.9 billion, Morningstar reported. The gap is narrowing fast.
SCHD has returned 29.99% year to date, outpacing the S&P 500’s 13.18%, according to Morningstar. VIG has returned 11.54%. Both carry 3-star Morningstar ratings. Both yield very differently — SCHD at 3.1% and VIG at just 1.5%.
So which one actually belongs in your portfolio? The answer, as with most things in investing, is that it depends on what you need it to do.
What SCHD is, and why it has run so hard this year
SCHD tracks the Dow Jones U.S. Dividend 100 Index, which screens companies on four financial quality metrics: cash flow to total debt, return on equity, dividend yield, and five-year dividend growth rate.Â
Entry requires 10 consecutive years of dividend payments. The top 102 qualifying stocks are selected and weighted based on Schwab‘s fund disclosures.
That process has produced a portfolio edging heavily toward healthcare, consumer staples, energy, industrials, financials, and technology as top holdings, according to Morningstar.
The top holdings tell the story: Merck, Amgen, Abbott Laboratories, Coca-Cola, Chevron, ConocoPhillips, Verizon, UnitedHealth, Procter and Gamble, and Home Depot.Â
I see them as cheap, cash-generative, lower-volatility businesses that got overlooked during the AI-fueled mega-cap tech run of 2023 and 2025, but that are now getting their turn.
A recent March portfolio reconstitution pushed SCHD even further into healthcare while trimming energy stocks. All of that, combined with a market that has rewarded defensives and value in 2026, explains most of the 29% run.
The honest caveat is that at roughly 19 times earnings and a 3.1% yield, according to Yahoo Finance, SCHD is no longer the dirt-cheap fund it was two years ago. The easy money from the “cheap value fund becomes a crowd favorite” repricing has largely happened.Â
YCharts shows that the 10-year Treasury currently yields around 4.7%. So an income-focused investor can get more current yield from government bonds without equity risk than from SCHD’s dividend alone.Â
That does not make SCHD a bad holding. It just means new buyers are getting a different deal than early holders got.
SCHD Dividend ETF held $113.2 billion in net assets as of Sept. 3, while VIG Dividend ETF sits at $130.9 billion.Hadayeva Sviatlana Via Shutterstock
What VIG is, and why the lower yield is intentional
VIG tracks the S&P U.S. Dividend Growers Index, which requires companies to have increased their dividends for at least 10 consecutive years and excludes the top 25% highest-yielding qualifiers to eliminate yield traps.Â
That sets it apart from SCHD, which tracks the Dow Jones U.S. Dividend 100 Index and focuses more heavily on fundamental financial strength and current dividend yield.Â
The result is that VIG’s portfolio is tilted toward high-quality companies with a stronger history of dividend growth, rather than simply maximizing higher current yields.
VIG’s top holdings include Broadcom at 4.62%, Apple at 4.44%, Microsoft at 4.33%, JPMorgan at 4.06%, and Eli Lilly at 3.92%, according to Morningstar data.
The fund’s sector breakdown shows Technology at 25.97%, Financial Services at 21.84%, Healthcare at 17.85%, and Industrials at 11.34%.
That technology and financials weighting is why VIG has returned only 11.54% in 2026 versus SCHD’s 29%. When the market rewards defensives, VIG underperforms. When mega-cap tech resumes leadership, VIG tends to hold up better.
The 1.5% current yield is the tradeoff. VIG is designed for investors who want dividend growth compounding over decades, accepting a lower starting income in exchange for broader sector diversification and historically lower volatility.
Which one actually wins for your portfolio?
The assets under management (AUM) race is a fun headline. But it is not a buy signal for either fund. Why? The real framework is purpose.
SCHD earns its place for investors drawing income now or approaching retirement. The worst situation in retirement is to be running out of money — the 3.1% yield and quarterly distributions do meaningful work.Â
But there’s a concentration risk to watch. SCHD is more dependent on healthcare today than it has been historically, and sector rotation could hurt it in a growth-led market.
VIG earns its place as a long-term compounder for those seeking quality exposure, a dividend growth engine, and lower sector concentration. The tradeoff is modest current income and underperformance in value-led markets like this one.
Neither VIG nor SCHD is obviously wrong. But investors in either fund should also know that VYM offers a broader, higher-yielding alternative and DGRO provides a dividend-growth screen without SCHD’s current pharma-heavy tilt.
The biggest fund in a category is not always the best investment. It is just the most popular one. Popularity and performance are different things, and in dividend investing, knowing which you are chasing matters most.
